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Mitochondrial neurogastrointestinal encephalomyop-
athy (MNGIE) is a rare autosomal recessive metabolic
disorder caused by a deficiency of thymidine phospho-
rylase (TP, EC2.4.2.4) due to mutations in the nuclear
gene TYMP. TP deficiency leads to plasma and tissue
accumulations of thymidine and deoxyuridine which
generate imbalances within themitochondrial nucleotide
pools, ultimately leading to mitochondrial dysfunction.1
MNGIE is characterized clinically by leukoencephalop-
athy, external ophthalmoplegia, peripheral polyneuropa-
thy, cachexia, and enteric neuromyopathy manifesting as
gastrointestinal dysmotility. The condition is relentlessly
progressive, with patients usually dying from a combi-
nation of nutritional and neuromuscular failure at an
average age of 37 years.2 Allogeneic hematopoietic stem
cell transplantation (AHSCT) offers a permanent cure.
Clinical and biochemical improvements following
AHSCT have been reported but it carries a high mor-
tality risk and is limited by matched donor availability.3
A consensus proposal for standardizing AHSCT recom-
mends treatment of patients without irreversible end-
stage disease and with an optimally matched donor; a
majority of patients are ineligible and thus there is a
critical requirement for an alternative treatment.4
We report a compassionate use of erythrocyte
encapsulated recombinant Escherichia coli TP (EE-
TP). In this approach, a predetermined volume of
the patient’s blood is removed and subjected to
reversible hypo-osmotic dialysis to enable encapsula-
tion of TP within the erythrocytes, which are then
returned to the patient.5,6 EE-TP has the pharmaco-
logic advantages of prolonging the circulatory half-life
of TP and minimizing immunogenic reactions.
Level of evidence. This is a single observational
study without controls and provides Class IV evi-
dence that EE-TP provides clinical benefit.
Case report. The patient was reported previously by
Filosto et al.7 An initial diagnosis of an inflammatory
polyneuropathy was made; corticosteroids, immuno-
globulins, and cyclophosphamide were administered
without clinical benefit. At age 26 years, a compound
heterozygous TYMP mutation was demonstrated.
Clinical assessment prior to initiating EE-TP con-
firmed peripheral sensorimotor polyneuropathy,
external ophthalmoplegia, minimum intestinal dys-
motility, and difficulties in walking a distance of
1 km. At age 28 years, he received his first infusion
of EE-TP; a mean thymidine phosphorylase activity
of 17 IU/kg was administered and this was gradually
escalated to 46 IU/kg in cycle 30 (27 months). Research
ethics committee approval and patient informed consent
were obtained.
Results. Pretherapy plasma concentrations of thymi-
dine and deoxyuridine were reduced from 20.5 and
30.6mmol/L, respectively, to intracycle values less than
8.1 and 12.6 mmol/L for thymidine and deoxyuridine,
respectively (figure, A). Urinary thymidine and deox-
yuridine excretion decreased from pretreatment values
of 421 and 324 mmol/24 hours, respectively, to mid-
cycle levels between 192 and 282 mmol/24 hours for
thymidine and 0.0–184 mmol/24 hours for deoxyuri-
dine from cycle 21 onwards. Toward the end of the
treatment cycles, the metabolites returned to abnormal
values, a consequence of a decrease in circulating eryth-
rocyte TP activity.
Clinical assessments between 6.5 and 23 months
after initiating EE-TP revealed significant improve-
ments. The Medical Research Council sumscore for
power increased from 56 to 74 (figure, B). There were
improvements in gait and balance, sensory ataxia, and
fine finger function; body weight increased from 57.4 kg
to 61.2 kg. Coinciding with this clinical improvement
and of possible significance, there was a steady fall in
plasma creatine kinase activity from 1,200 U/L pre-
therapy to 254 U/L (normal range 40–320 U/L) at
23 months. The patient-reported outcomes after 23
months included being able to walk 10 km, climb
stairs without assistance, tie shoelaces, and feel the
sensation of sand on his feet when walking on beach.
He has also returned to weight training and resumed
playing guitar in a local band. The previously reported
numbness in hands and feet also resolved. Nerve con-
duction and EMG studies at baseline and 27 months
did not show any significant changes in spite of the
significant clinical improvements.
The only adverse events observed were mild reac-
tions (coughing and erythema of the face and neck) to
the enzyme infusion; these were transient, occurring
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within 5 minutes of infusion, and easily managed by
premedication with antihistamine and glucocorti-
coids. The introduction of a highly purified enzyme
largely eliminated these reactions, permitting a grad-
ual withdrawal of the premedication. No circulating
anti-TP antibodies were detected.
Discussion. This report describes a successful enzyme
replacement therapy for MNGIE. Although EE-TP
strongly reduced plasma nucleosides without eliminat-
ing them to undetectable levels, significant clinical
improvements were noted, as observed in patients
who underwent AHSCT,2 suggesting a greater muscle
mitochondrial oxidative function. EE-TP should be
considered as a rescue or maintenance therapy prior
to the availability of a suitable AHSCT donor or as
an alternative therapy for patients who have irreversible
end-stage disease and are without an optimally
matched donor. Clinical trials with this form of ther-
apy are indicated.
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Figure Plasma nucleosides and MRC sumscore before and during treatment with EE-TP
(A) Plasma concentrations of thymidine and deoxyuridine during 27 treatment cycles of Escherichia coli thymidine phos-
phorylase (EE-TP). (B) Medical Research Council (MRC) scale in different muscle groups before and during 27 treatment
cycles of EE-TP.
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